A continuous perfusion platform for retinal disease models: PANDORA

Author

Celeste Chidiac

Publication Date

October 2, 2026

Keywords

retinal disease models

blindness

organoids

Age-related macular degeneration

tissue explants

drug delivery

fine-tuned flow control

shear stress

Your microfluidic SME partner for Horizon Europe

We take care of microfluidic engineering, work on valorization and optimize the proposal with you 

Microfluidics for retinal models: introduction

Age-related macular degeneration (AMD) is a leading cause of blindness in the elderly, affecting the daily life of around 200 million people worldwide. The complement system, part of innate immune surveillance, has emerged as a major pathogenic driver of the disease. To study these mechanisms and test new therapies, researchers rely on advanced in vitro retinal models such as organoids and tissue explants. Conventional static cultures, however, supply nutrients in excess at fixed timepoints, usually every two days, which is far from physiological. Continuous perfusion of culture media offers much closer-to-native conditions, and this is where microfluidics becomes essential.

PANDORA-retinal-disease

Understanding and treating AMD: the PANDORA project

PANDORA is a Horizon Europe MSCA Doctoral Network coordinated by Eberhard Karls Universität Tübingen (Germany), bringing together eight academic, three industrial and two non-profit organisations across Europe for 48 months. The network studies complement-mediated pathomechanisms of AMD and develops new therapeutic approaches. It exploits state-of-the-art model systems and techniques, including ex vivo multicellular, stem cell-derived and murine models, omics, imaging, biochemistry, histology, functional assays and computational modelling, to study the complement functions relevant to AMD and to identify biomarkers for patient stratification and disease monitoring. In parallel, PANDORA develops innovative therapies through gene therapy, compound screening, optimised drug delivery to the retina and a novel multimodality imaging system. Through this work, the network trains the next generation of European translational scientists in vision and medical research.

Continuous perfusion of retinal models: our role

Within PANDORA, MIC hosts Doctoral Candidate 5 (DC5), whose PhD project focuses on the development of a novel instrument for the continuous perfusion of in vitro retinal models. DC5 will design a microfluidic setup for the automated perfusion of retinal organoid and retinal tissue explant cultures. The system will combine fine-tuned flow control to minimise shear stress with a media circulation loop for perfusion over long periods, reducing costs while benefiting complex cell-culture treatments. The project will also explore additional features such as in-line pH and O₂ sensors to monitor and control the cellular microenvironment, a temperature-controlled chamber and bubble traps to prevent air entrapment in the perfusion loop. In parallel, DC5 will study how a dedicated flow and gas controller can reproduce the hypoxic conditions seen in AMD. The perfusion system will be tested and validated with consortium partners on multicellular complex cultures.

MSCA logo
PANDORA logo

Funding and Support

This project has received funding from the Horizon Europe, MSCA Doctoral Networks HORIZON-MSCA-2025-DN-01-01, grant agreement no. 101312030

Start date: 1 October 2026

End date: 30 September 2030

About the author

Celeste Chidiac

Céleste Chidiac, PhD
Scientific writer and digital marketing specialist

Céleste Chidiac holds a doctorate in neuroscience and molecular biology from the University of Strasbourg. Since joining the Microfluidics Innovation Center in 2023, she has combined scientific writing with website management. Her reviews draw on published research to explain microfluidic technologies, compare experimental approaches and discuss their applications and limitations. She helps researchers understand how these methods work and assess their relevance to their own research.

Check our Projects

FAQ – PANDORA retinal models and continuous perfusion

Experimental choices and measurement limits when studying retinal tissue under controlled flow.

How do retinal organoids differ from retinal explants?

Retinal organoids develop from stem cells; explants are pieces of existing retinal tissue maintained outside the body. Their maturity, cell composition and experimental limitations differ.

No. Circulating medium around an organoid provides external fluid exchange. A functional internal vascular network requires separate biological development and validation.

No. Recirculation reuses medium. Nutrients can be depleted and metabolites can accumulate, so medium renewal remains necessary according to the culture’s needs.

No. Faster flow can increase mechanical stress and alter exposure. Flow should match the tissue, chamber geometry and experimental objective.

Cellular oxygen consumption, diffusion distances and flow affect local oxygen levels. Measurements must relate to the tissue compartment, not only the incubator or reservoir.

Bubbles can obstruct channels, change flow and interrupt liquid contact with tissue. Bubble management should therefore be checked throughout long experiments.

Tubing and chip materials can retain compounds, while mixing and medium renewal change exposure over time. Nominal reservoir concentration may therefore differ from local exposure.

Flow and medium replacement can alter the concentration and residence time of soluble complement proteins. These conditions should be documented when comparing complement activity.

No. Viability does not establish retinal identity or function. Relevant checks can include cell composition, tissue organisation and functional responses appropriate to the intended experiment.

Compare matched cultures with and without perfusion while documenting medium renewal, tissue maturity and exposure duration. Keep treatment and disease comparisons separate from changes in culture conditions.

Main-Logo-MIC-PURPLE